A positive reimbursement decision has paved the way for Bavencio (avelumab) plus Inlyta (axitinib) to be made available for people with kidney cancer in the UK.
Germany’s Merck KGaA (MRK: DE) and New York-based Pfizer (NYSE: PFE) won European approval for the combination as a first-line treatment for advanced renal cell carcinoma (RCC) in late 2019.
While the combo has been available since then through the UK’s Early Access to Medicines Scheme (EAMS), the decision secures long-term funding through the Cancer Drugs Fund, a special resource for oncology treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze